Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3086657
Max Phase: Preclinical
Molecular Formula: C25H43N9O7
Molecular Weight: 581.68
Molecule Type: Protein
Associated Items:
ID: ALA3086657
Max Phase: Preclinical
Molecular Formula: C25H43N9O7
Molecular Weight: 581.68
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(N)=O
Standard InChI: InChI=1S/C25H43N9O7/c1-13(2)19(26)24(41)34-11-5-8-17(34)22(39)32-15(12-18(35)36)23(40)33-10-4-7-16(33)21(38)31-14(20(27)37)6-3-9-30-25(28)29/h13-17,19H,3-12,26H2,1-2H3,(H2,27,37)(H,31,38)(H,32,39)(H,35,36)(H4,28,29,30)/t14-,15-,16-,17-,19-/m0/s1
Standard InChI Key: BNJQXMQEEHPMKI-WSRJKRBPSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 581.68 | Molecular Weight (Monoisotopic): 581.3285 | AlogP: -2.86 | #Rotatable Bonds: 14 |
Polar Surface Area: 267.13 | Molecular Species: ZWITTERION | HBA: 8 | HBD: 8 |
#RO5 Violations: 2 | HBA (Lipinski): 16 | HBD (Lipinski): 11 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 4.01 | CX Basic pKa: 11.74 | CX LogP: -5.31 | CX LogD: -6.16 |
Aromatic Rings: 0 | Heavy Atoms: 41 | QED Weighted: 0.06 | Np Likeness Score: 0.02 |
1. Heard KR, Wu W, Li Y, Zhao P, Woznica I, Lai JH, Beinborn M, Sanford DG, Dimare MT, Chiluwal AK, Peters DE, Whicher D, Sudmeier JL, Bachovchin WW.. (2013) A general method for making peptide therapeutics resistant to serine protease degradation: application to dipeptidyl peptidase IV substrates., 56 (21): [PMID:24044354] [10.1021/jm400423p] |
Source(1):